Douglas Lane & Associates LLC cut its stake in shares of Core Laboratories (NYSE:CLB) by 66.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,285 shares of the oil and gas company’s stock after selling 4,610 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Core Laboratories were worth $250,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in shares of Core Laboratories during the 2nd quarter valued at approximately $474,000. Goldman Sachs Group Inc. grew its holdings in shares of Core Laboratories by 30.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 89,829 shares of the oil and gas company’s stock valued at $9,096,000 after purchasing an additional 21,006 shares during the last quarter. Marble Harbor Investment Counsel LLC grew its holdings in shares of Core Laboratories by 4.9% during the 3rd quarter. Marble Harbor Investment Counsel LLC now owns 10,976 shares of the oil and gas company’s stock valued at $1,083,000 after purchasing an additional 510 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in Core Laboratories during the 2nd quarter worth approximately $426,000. Finally, HighTower Advisors LLC boosted its position in Core Laboratories by 13.5% during the 2nd quarter. HighTower Advisors LLC now owns 10,869 shares of the oil and gas company’s stock worth $1,102,000 after buying an additional 1,290 shares during the period.

Several research firms recently commented on CLB. UBS Group cut their target price on shares of Core Laboratories from $110.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 25th. Royal Bank of Canada reiterated a “buy” rating on shares of Core Laboratories in a research report on Wednesday, October 18th. Deutsche Bank began coverage on shares of Core Laboratories in a research report on Tuesday, October 10th. They set a “buy” rating and a $109.00 target price on the stock. Cowen set a $100.00 target price on shares of Core Laboratories and gave the stock a “hold” rating in a research report on Friday, October 6th. Finally, ABN Amro upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $110.20.

Shares of Core Laboratories (NYSE:CLB) opened at $119.10 on Friday. The company has a market cap of $5,260.00, a P/E ratio of 68.84 and a beta of 1.56. Core Laboratories has a 1 year low of $86.55 and a 1 year high of $123.95. The company has a current ratio of 2.18, a quick ratio of 1.81 and a debt-to-equity ratio of 1.53.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Friday, January 26th will be given a $0.55 dividend. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.85%. Core Laboratories’s dividend payout ratio (DPR) is currently 127.17%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/douglas-lane-associates-llc-decreases-position-in-core-laboratories-clb/1825111.html.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.